Medisafe Announces Launch of GOMEKLI™ Digital Companion to Support Patients with NF1-PN Taking GOMEKLI
BOSTON, MA / May 13, 2025 / Medisafe, the leading digital health platform for medication engagement, today announced a collaboration with SpringWorks Therapeutics to launch the GOMEKLI™ (mirdametinib) Digital Companion by Medisafe—an innovative, behaviorally driven platform designed to support GOMEKLI patients living with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (NF1-PN).
The GOMEKLI Digital Companion delivers a personalized, connected experience for patients and caregivers navigating complex treatment journeys. The platform integrates Medisafe’s proprietary Just-In-Time Interventions (JITI™) technology to deliver timely support, educational content, proactive medication tracking, and seamless integration with SpringWorks’ patient services program, SpringWorks CareConnections™ .
“This collaboration reflects our shared commitment to transforming patient engagement through digital innovation,” said Stacey Wasserman, Chief Commercial Officer of Medisafe. “By bringing our JITI-powered experience to GOMEKLI patients, we are not only helping them stay on track with therapy but giving them real-time tools to take control of their health and feel supported every step of the way.”
Through the GOMEKLI Digital Companion, patients can receive personalized reminders, educational resources, and real-time updates on coverage status. They can easily request a call from their dedicated Nurse Advocate—enabling faster, more connected support at the tap of a button.
“Partnering with Medisafe allows us to offer a personalized, tech-forward experience that empowers individuals and families affected by NF1-PN to stay engaged and confident throughout their treatment,” said Laura Smith, Director, US Marketing at SpringWorks Therapeutics. “
About Medisafe
Medisafe is the leading medication engagement company that empowers patients to seamlessly manage their treatment journey and holistic health to drive outcomes, while providing real-time intelligence from a database of billions of data points. By combining advanced technology with behavioral science, Medisafe’s multiple options support patients, providers, and payers at-scale by supporting better engagement, health management, and outcomes. Over 13M registered patients and caregivers rely on Medisafe’s HIPAA and GDPR compliant solution, which is also ISO 27001:2013 and ISO 13845 certified.
For media inquiries, please contact:
[email protected]
SOURCE: Medisafe
GOMEKLI (mirdametinib) is a prescription medicine used to treat adults and children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cause symptoms and cannot be completely removed by surgery.
It is not known if GOMEKLI is safe and effective in children under 2 years of age.
Before taking GOMEKLI, tell your healthcare provider about all of your medical conditions, including if you:
-
- Have eye problems
- Have heart problems
- Are pregnant or plan to become pregnant. GOMEKLI can harm your unborn baby
Females who are able to become pregnant:
- Your healthcare provider should check to see if you are pregnant before you begin treatment with GOMEKLI.
- Use effective birth control (contraception) during treatment with GOMEKLI and for 6 weeks after your last dose.
- Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with GOMEKLI.
Males with female partners who are able to become pregnant:
- Use effective birth control (contraception) during treatment with GOMEKLI and for 3 months after your last dose.
- Tell your healthcare provider right away if your female partner becomes pregnant or thinks she may be pregnant during treatment with GOMEKLI.
-
- Are breastfeeding or plan to breastfeed. It is not known if GOMEKLI passes into your breast milk.
- Do not breastfeed during treatment with GOMEKLI and for 1 week after your last dose.
- Talk to your healthcare provider about the best way to feed your baby during this time.
- Are breastfeeding or plan to breastfeed. It is not known if GOMEKLI passes into your breast milk.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
-
- Take GOMEKLI exactly as your healthcare provider tells you to take it. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with GOMEKLI if you develop certain side effects.
-
- Take GOMEKLI twice a day, about 12 hours apart, for 21 days, followed by 7 days off treatment, to complete a 28-day treatment cycle. Your healthcare provider will decide how many treatment cycles are right for you.
-
- Take GOMEKLI with or without food.
-
- GOMEKLI comes in two different dosage forms, GOMEKLI capsules and GOMEKLI tablets for oral suspension. Your healthcare provider will decide the dosage form and dose of GOMEKLI that is right for you.
-
- If you take GOMEKLI capsules: Swallow each capsule whole with drinking water. If more than 1 capsule is required, swallow 1 capsule at a time. Do not open, break or chew the capsules.
-
- If you take GOMEKLI tablets for oral suspension, either:
-
- Swallow each tablet for oral suspension whole with drinking water. If more than 1 tablet is required, swallow 1 tablet at a time.
OR
-
- Disperse the tablets for oral suspension in drinking water to make a liquid (suspension) before you take or give GOMEKLI.
See the “Instructions for Use” that come with your medicine for instructions on how to prepare and take GOMEKLI tablets for oral suspension.
-
- If you take GOMEKLI tablets for oral suspension, either:
-
- If you miss a dose of GOMEKLI, skip the missed dose and take your next dose at your regularly scheduled time.
-
- If you vomit at any time after taking GOMEKLI, do not take an additional dose. Take your next dose at your regularly scheduled time.
- Eye problems. GOMEKLI may cause eye problems that can lead to blindness. Your healthcare provider will check your vision before and during treatment with GOMEKLI. Tell your healthcare provider right away if you get any of the following signs or symptoms of eye problems:
-
- Blurred vision
-
- Loss of vision
-
- Other changes to your vision
-
- Heart problems. GOMEKLI may lower the amount of blood pumped by your heart, which is common in children during treatment with GOMEKLI and can also be severe. Your healthcare provider will do tests before you start GOMEKLI treatment, every 3 months during your first year of treatment, and then as needed to make sure your heart is working properly. Tell your healthcare provider right away if you get any of the following signs or symptoms of heart problems:
-
- Coughing or wheezing
-
- Shortness of breath
-
- Swelling of your ankles and feet
-
- Tiredness
-
- Increased heart rate
-
- Skin problems. Skin rashes are common with GOMEKLI in both adults and children and can also be severe. GOMEKLI can also cause hair loss (alopecia). Tell your healthcare provider if you develop any of the following signs or symptoms of skin problems:
-
- Flat skin rash
-
- Raised bumps on the skin
-
- Skin bumps that look like acne
-
- Skin redness
-
- Itchy rash
-
- Peeling skin
-
-
- Diarrhea
-
- Nausea
-
- Muscle, joint, and bone pain
-
- Vomiting
-
- Tiredness
The most common severe abnormal blood tests in adults include an increased enzyme called creatine phosphokinase (CPK).
-
- Diarrhea
-
- Muscle, joint, and bone pain
-
- Stomach (abdominal) pain
-
- Vomiting
-
- Headache
-
- Skin redness, swelling, or pain around the fingernails or toenails
-
- Nausea
The most common severe abnormal blood tests in children include decreased white blood cell (neutrophil) counts and increased CPK.
These are not all of the possible side effects of GOMEKLI. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.